The Week

Thermo Fisher (TMO) gained 6.83% this week to close at $651.45, outperforming the S&P 500, which slipped 0.08%, by roughly 6.91 percentage points. The move was a step-like rally rather than a straight line. Monday opened at $614.94 and dipped to $605.65, then Tuesday jumped 4.52% to $641.39 on heavier volume. Wednesday and Thursday added more upside, with Thursday touching an intraday high of $663.57 before Friday eased back to $651.45. Weekly amplitude came in at 9.42%, and average daily volume of about 3.19 million shares ran roughly 72% above the 60-day median, pointing to unusually active trading.

Key Events

Several items this week centred on management’s upbeat tone for 2026. On 15 September, reports highlighted strong Q2 growth, AI-driven demand and reshoring trends as supports for a multi-year outlook, and the stock rose 3.44%. On 17 September, the company said it expects stronger demand and called 2026 an ‘outstanding year’. The next day, during regular trading, the stock reached a 52-week high, with management signalling a positive biopharma growth outlook. Friday brought a pullback and underperformance. The storyline was consistent: company-level comments focused on biopharma demand and AI-related opportunities, and the share price moved higher in tandem, setting a 52-week high midweek.

Analyst Ratings

Among 31 analysts covering the stock, 20 rate it buy, 4 rate it outperform, 4 rate it hold, 1 rates it underperform, 2 have no opinion, and none rate it sell. The consensus rating is buy, with a consensus target of $645.15, about 0.97% below the latest price of $651.45. That means the stock now trades slightly above the average analyst target. Targets range from $520 to $750, a wide spread that reflects disagreement about the longer-term upside. Within the life science tools and services industry, TMO ranks first among 54 companies.

The Week Ahead

The macro calendar is relatively quiet next week. The main US releases fall on 24 September: initial jobless claims, the current account balance and new home sales. After management’s stronger-demand comments this week, the focus will be on whether that optimism gets backed up by more supply-chain data, along with any fresh signs on biopharma orders and AI-related demand. Another angle is price action near the highs: shares set a 52-week high on Thursday and pulled back on Friday, so how the stock behaves around record levels will be worth tracking.

In Short

The tension this week is between a fresh 52-week high and a consensus target that now sits below the spot price. Analysts still collectively rate the stock a buy and place it first in its industry, but the consensus target of $645.15 is slightly under the latest close, meaning the average expected upside has narrowed after the run-up. On the latest trading day, large orders were net buyers by about $30.61 million, with small and medium orders also net inflows, so short-term participation had not faded. The question going forward is whether management’s strong demand outlook translates into verifiable orders and revenue, and how well the stock holds near record levels.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.